Skip to main content
Log In
More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
Basket
Search
More
Search for this keyword
Advanced search
Latest content
Browse by collection
Archive
Authors
About
Search for this keyword
Advanced search
Close
More
Main menu
Latest content
Browse by collection
Archive
Authors
About
Log in
More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
BMJ Journals
You are here
Home
Archive
Volume 10, Issue 3
Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer
Email alerts
Article metrics
Article menu
Article
Text
Article
info
Citation
Tools
Share
Rapid Responses
Article
metrics
Alerts
PDF
PDF +
Supplementary
Material
Clinical/translational cancer immunotherapy
Original research
Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer
Online download statistics by month:
Online download statistics by month: March 2022 to April 2023
Abstract
Full
Pdf
Mar 2022
551
568
274
Apr 2022
275
286
121
May 2022
219
221
106
Jun 2022
223
234
92
Jul 2022
205
218
77
Aug 2022
219
223
69
Sep 2022
235
238
225
Oct 2022
243
248
102
Nov 2022
180
183
59
Dec 2022
161
160
63
Jan 2023
150
150
63
Feb 2023
182
182
78
Mar 2023
136
137
90
Apr 2023
113
113
86
Total
3092
3161
1505
Read the full text or download the PDF:
Subscribe
Log in
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?